Metronidazol Normon (Metronidazole)

Metronidazole is taken up by anaerobic microorganisms and reduced by their intracellular proteins, forming nitro radicals that damage DNA and inhibit nucleic acid synthesis, ultimately leading to microbial cell death.

The specific dose and infusion rate of Metronidazol Normon are determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and local treatment guidelines.

Metronidazole is classified as a pregnancy‑category drug with limited data; it should be used only when the potential benefit justifies any potential risk to the fetus. Breastfeeding mothers should consult a healthcare professional, as the drug is excreted in milk.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Metronidazole offers rapid bactericidal activity against a broad range of anaerobes and protozoa, often with fewer dosing intervals than beta‑lactam combinations. It is particularly effective where resistance to other agents is a concern, but clinicians may choose alternative agents based on susceptibility patterns, patient allergies, or site‑specific considerations.

Store the product at ambient temperature, below 25 °C, in its original packaging. Protect it from direct sunlight, moisture, and extreme temperature fluctuations. Follow aseptic techniques during preparation and administration to maintain sterility.

Metronidazol Normon is administered intravenously by slow infusion, typically over 30‑60 minutes, under the supervision of qualified healthcare personnel. The exact infusion rate and duration are set by the prescribing clinician according to the therapeutic indication.

Serious risks include severe allergic reactions (anaphylaxis), seizures, neutropenia, Stevens‑Johnson syndrome, hepatic toxicity, and peripheral neuropathy. Patients should be monitored for rash, neurological changes, liver function abnormalities, and signs of bleeding, especially if taking anticoagulants.

Metronidazol Normon should be avoided in patients with known hypersensitivity to metronidazole or other nitroimidazoles, those with severe hepatic impairment, and individuals who are unable to abstain from alcohol during therapy due to the risk of a disulfiram‑like reaction.